Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 4/20 | 0.83 |
| ▸ | CNR1 | P21554 | 2/20 | 0.34 |
| ▸ | TACR1 | P25103 | 2/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.31 |
| ▸ | DUT | P33316 | 1/20 | 0.31 |
| ▸ | CMA1 | P23946 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL176431 | 1.00 | CNR2 (0.83) | CNR2CNR1TACR1TBXA2RPTGDR | |
| SCHEMBL13011098 | 0.99 | CNR2 (0.82) | CNR2CNR1TACR1TBXA2RPTGDR | |
| SCHEMBL13011083 | 0.91 | CNR2 (0.70) | CNR2CNR1MAPK1 | |
| SCHEMBL176578 | 0.91 | CNR2 (1.00) | CNR2TACR1TBXA2RPTGDRDUT | |
| SCHEMBL176472 | 0.91 | CNR2 (1.00) | CNR2TACR1TBXA2RPTGDRDUT | |
| SCHEMBL257655 | 0.91 | CNR2 (1.00) | CNR2TACR1TBXA2RPTGDRDUT | |
| SCHEMBL300529 | 0.91 | CNR2 (1.00) | CNR2TACR1TBXA2RPTGDRDUT | |
| SCHEMBL13745252 | 0.91 | CNR2 (1.00) | CNR2TACR1TBXA2RPTGDRDUT | |
| SCHEMBL13745064 | 0.88 | CNR2 (0.65) | CNR2TACR1TBXA2RPTGDRCCR5 | |
| SCHEMBL176561 | 0.87 | CNR2 (0.85) | CNR2TBXA2RPTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8378096-B2 | Hexahydro-cycloheptapyrazole cannabinoid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-02-19 | — | — | US | disclosed |
| US-20090197886-A1 | HEXAHYDRO-CYCLOHEPTAPYRAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197886-A1 | HEXAHYDRO-CYCLOHEPTAPYRAZOLE CANNABINOID MODULATORS | CNR2, CNR1, FAAH | CNR2 1/4885CNR1 2/4885TACR1 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.